| 2026-06-12 | Mr. Christopher Ian Charles SmithCEO & Executive Director | -246,45k | 480,55k | Derivative Exercise and Sale | 1,95 | 2,02M | - |
| 2026-06-12 | Mr. Christopher Ian Charles SmithCEO & Executive Director | 275,81k | 0,00 | Derivative Exercise and Retained Stock | - | 2,02M | 15,80% |
| 2026-06-11 | Mr. Christopher Ian Charles SmithCEO & Executive Director | 99,13k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | - | - |
| 2025-12-01 | Mr. Mark William StricklandCFO & Executive Director | 3,79k | 6,32k | Kauf | 1,67 | 851,79k | 0,45% |
| 2025-10-21 | Mr. Christopher Ian Charles SmithCEO & Executive Director | -842,65k | 1,38M | Verkauf | 1,63 - 1,65 | 1,75M | -32,55% |
| 2025-10-21 | Mr. Mark William StricklandCFO & Executive Director | -471,93k | 771,22k | Verkauf | 1,63 - 1,65 | 848,01k | -35,75% |
| 2025-10-21 | Mr. Peter IngelseManaging Director of Liquids | -224,67k | 368,64k | Verkauf | 1,63 - 1,65 | 530,22k | -29,76% |
| 2025-10-21 | Mr. Lennard MarkesteinManaging Director of Unit Dosing | -236,49k | 388,04k | Verkauf | 1,63 - 1,65 | 578,83k | -29,01% |
| 2025-10-21 | Marielle ClaudonManaging Director of Powders | -157,41k | 258,16k | Verkauf | 1,63 - 1,65 | 256,86k | -38,00% |
| 2025-10-07 | Mr. Christopher Ian Charles SmithCEO & Executive Director | 1,79M | 0,00 | Derivative Exercise and Retained Stock | - | 2,59M | 222,23% |
| 2025-10-07 | Mr. Mark William StricklandCFO & Executive Director | 999,67k | 0,00 | Derivative Exercise and Retained Stock | - | 1,32M | 312,14% |
| 2025-10-07 | Mr. Peter IngelseManaging Director of Liquids | 464,05k | 0,00 | Derivative Exercise and Retained Stock | - | 754,89k | 159,56% |
| 2025-10-07 | Mr. Lennard MarkesteinManaging Director of Unit Dosing | 500,49k | 0,00 | Derivative Exercise and Retained Stock | - | 815,31k | 158,97% |
| 2025-10-07 | Marielle ClaudonManaging Director of Powders | 299,71k | 0,00 | Derivative Exercise and Retained Stock | - | 414,27k | 261,60% |